GRI Bio, Inc. (GRI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US3622AW5029
GRI Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -11.98 m USD |
| EBIT | -11.95 m USD |
| Net income | -11.96 m USD |
| Diluted EPS – continuing operations | -121.80 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
More stocks
- Tenon Medical, Inc. (TNON)
- BIOXYTRAN, INC (BIXT)
- NAPC Defense, Inc. (BLIS)
- MOBIVITY HOLDINGS CORP. (MFON)
- Premier Air Charter Holdings Inc. (PREM)
- AIBOTICS, INC. (AIBT)
- FARMHOUSE, INC. /NV (FMHS)
- Ernexa Therapeutics Inc. (ERNA)
- KwikClick, Inc. (KWIK)
- ADIAL PHARMACEUTICALS, INC. (ADIL)
- VACCINEX, INC. (VCNX)
- Medicus Pharma Ltd. (MDCX)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.